Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening

Add time:08/14/2019    Source:sciencedirect.com

Insulin-degrading enzyme, IDE, is a metalloprotease implicated in the metabolism of key peptides such as insulin, glucagon, β-amyloid peptide. Recent studies have pointed out its broader role in the cell physiology. In order to identify new drug-like inhibitors of IDE with optimal pharmacokinetic properties to probe its multiple roles, we ran a high-throughput drug repurposing screening. Ebselen, cefmetazole and rabeprazole were identified as reversible inhibitors of IDE. Ebselen is the most potent inhibitor (IC50 (insulin) = 14 nM). The molecular mode of action of ebselen was investigated by biophysical methods. We show that ebselen induces the disorder of the IDE catalytic cleft, which significantly differs from the previously reported IDE inhibitors. IDE inhibition by ebselen can explain some of its reported activities in metabolism as well as in neuroprotection.

We also recommend Trading Suppliers and Manufacturers of insulin, tri-Lys- (cas 12584-78-0). Pls Click Website Link as below: cas 12584-78-0 suppliers

Prev:Biochemical and molecular evidence on the role of vaspin in early detection of the insulin resistance in a rat model of high-fat diet and use of diazinon
Next:Effect of glycated insulin on the blood-brain barrier permeability: An in vitro study)